TABLE E1.
Characteristics of 16 22q11.2DS patients enrolled in the immunization study
| Characteristic | Value |
|---|---|
| Age (y), median (IQR) | 27 (24–36) |
| Sex, n (%) | 6 (60) |
| IgG (mg/dL), median (IQR) | 1,331 (1,110–1,427) |
| Under IgG replacement treatment, n (%) | 1 (6) |
| IgA (mg/dL), median (IQR) | 269 (196–314) |
| Selective IgA deficiency, n (%) | 1 (6) |
| IgM (mg/dL), median (IQR) | 69 (47–137) |
| Selective IgM deficiency, n (%) | 3 (20) |
| Lymphocytes, cells/mm3, median (IQR) | 1,835 (1,212–3,280) |
| CD4+ T cells/mm3, median (IQR) | 716 (576–979) |
| CD8+ T cell/mm3, median (IQR) | 395 (304–449) |
| CD19+ B cells/mm3, median (IQR) | 276 (149–337) |
| Switched MBC % of IgM-MBCs, median (IQR) | 32 (21.6–39.3) |
| Clinical-associated conditions, n (%) | |
| Previous heart surgery | 8 (53) |
| CHD | 7 (47) |
| Hypertension | 4 (27) |
| DMT | 2 (13) |
| Dyslipidemia | 3 (20) |
| Psychiatric problems | 3 (33) |
| Neurological problems | 2 (13) |
| Learning issues | 9 (60) |
| Autoimmunity | 7 (47) |
| ITP/AIHA | 1 (7) |
| Arthritis | 1 (7) |
| Thyroid disease | 4 (29) |
| Immunosuppressive treatment | 2 (12) |
CHD, Congenital heart disease; DMT, diabetes mellitus; IgG, -A, -M, immunoglobulin G, A, M; IQR, interquartile range; ITP/AIHA, idiopathic thrombocytopenic purpura/autoimmune haemolytic anemia; MBC, memory B cell.